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Objective: To assess same-day and delayed reports of pain intensity during and after second-trimester medical termination of
pregnancy (MTOP).
Study Design: A prospective randomized trial (217 women) comparing 1- and 2-day mifepristone–misoprostol intervals.
Results: Women reported intense pain [median visual analogue scale (interquartile range)] related to expulsion of the fetus [6 (0–10)].
Delayed reports of maximal pain described the pain as more intense than same-day reports [8 (3–10) vs. 7 (1–10), pb.001].
Conclusions: Most women reported and readily remembered intense pain associated with fetal expulsion during second-trimester MTOP.
Implications: Adequate, properly timed pain management during second-trimester MTOP is crucial.
© 2014 Elsevier Inc. All rights reserved.Keywords: Second trimester abortion; Medical abortion; Visual analogue scale; Pain; Recollection1. Introduction
Medical termination of pregnancy (MTOP) is associated
with more pain than surgical procedures performed under
general anesthesia [1]. This pain becomes more intense with
advancing gestation, and during second-trimester MTOP, the
maximum pain has been moderate to severe [1–3].
MTOP is widely used, safe and very little dependent on the
skills of the medical staff performing it [1,4,5]. Pain relief
during the procedure needs attention, and studies on pain
management during second-trimester medical TOP are
sparse [6]. This study assessed pain intensity during or after
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were investigated.2. Materials and methods
These data were derived from a prospective randomized
trial of 227 women comparing 1- and 2-day mifepristone–
misoprostol interval in second-trimester MTOP at Helsinki
University Central Hospital between 2008 and 2010 [2].
The trial had approvals from the Ethics Committee of the
Hospital District of Helsinki and Uusimaa, and the Finnish
National Agency for Medicines.
MTOPwas performed using a 200-mg dose ofmifepristone
and 400-mcg repeat doses of misoprostol. During misoprostol
administration, women were in-patients until abortion. Pain
during MTOP was managed with the following:
1. A prophylactic dose of oral paracetamol (500 mg) plus
dihydrocodeine (10 mg) and ibuprofen (600–800 mg)
with first misoprostol dose
2. First-line analgesics: ibuprofen (up to 1800 mg per day)
on request
able 1
emographics of the 217 women undergoing second-trimester MTOP
uring 2008 to 2010
ariable 1-daya group,
n=114 (52.5)
2-daya group,
n=103 (47.5)
eeks of gestation 15 (14–17) 16 (14–18)
ge (years) 24 (21–29) 23 (20–29)
arital status
Married or cohabiting 35 (30.7) 35 (34.0)
Single 79 (69.3) 68 (66.0)
ocioeconomic status
White-collar workers 11 (9.6) 13 (12.6)
Blue-collar workers 40 (35.1) 37 (35.9)
Students 29 (25.4) 25 (24.3)
Others 34 (29.8) 28 (27.2)
ody mass index (kg/m2) 23 (21–26) 23 (20–25)
revious pregnancies
Termination of pregnancy 54 (47.4) 44 (42.7)
Vaginal deliveries 38 (33.3) 25 (24.3)
moking 66 (57.9) 66 (64.1)
dication for TOP
Fetal 7 (6.1) 8 (7.8)
Social 107 (93.9) 95 (92.2)
duction-to-abortion time (hours) 8 (6–12) 7 (5–9)
vacuation of placenta during TOP
(under general anesthesia)
29 (25.4) 39 (37.9)
umber of misoprostol doses
before fetal expulsion
1–3 61 (53.5) 38 (36.9)
4 or more 53 (46.5) 65 (63.1)
oute of misoprostol administration
Mostly vaginal 106 (93.0) 95 (92.2)
Mostly oral or sublingual 8 (7.0) 8 (7.8)
610 M. Mentula et al. / Contraception 90 (2014) 609–6113. Opioids on request: oxycodone hydrochloride (4 mg iv;
10 mg po), pethidine hydrochloride (50–75 mg) or
tramadol hydrochloride (50–100 mg)
4. Ibuprofen up to a dose of 1800 mg per day at home
on request
Pain was assessed using a numerical visual analogue scale
(VAS) of 0 (no pain) to 10 (the worst possible pain one could
imagine) before administration of each dose of mifepristone,
misoprostol or analgesics. At a follow-up assessment (2–4
weeks after), VAS scores for pain at home and at the follow-
up visit, as well as the use of analgesics at home were asked.
The highest pain VAS scores were reported and classified
into various time periods as follows:
1. Before first misoprostol dose (at the onset of first
misoprostol dose)
2. Before fetal expulsion (during repeat doses of
misoprostol)
3. Around fetal expulsion (30 min before and during
fetal expulsion)
4. After fetal expulsion (10 min or more after fetal expulsion)
5. At home
6. At the follow-up visit
The women were asked to rank their satisfaction with the
overall treatment of pain during MTOP with a scale of 4–10
(poor to excellent).ata are presented as n (%) or median (IQR).
a Mifepristone–misoprostol interval (per protocol).3. Statistical analysis
PASW 18.0 for Mac (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Nonparametric data are presented
as medians [interquartile range (IQR)]. Differences in contin-
uous variables were analyzed by using the Mann–Whitney U,
Wilcoxon and Friedman tests, as appropriate. Statistical
significance was defined as pb.05.ig. 1. Reportedmedian pain intensity scores on a numerical VAS (VAS 0–10)
mong 217 women undergoing second-trimester MTOP. Data are shown as
edianmaximumVAS scores and interquartile ranges at observed time points.4. Results
This analysis involved 217women, and one-fifth of patients
did not attend the follow-up visit [2]. The 1-day mifepristone–
misoprostol interval group had more women with previous
vaginal deliveries, less evacuations of placenta and less repeat
misoprostol doses than the 2-day group (Table 1).
Reports of intense pain were related to expulsion of the
fetus (Fig. 1). The reported VAS scores before the first
misoprostol dose or during repeat misoprostol administration
were low, until shortly before fetal expulsion (pb.001).
Similarly, after fetal expulsion, at home or at the follow-up
visit, the pain VAS scores were low.
The maximal same-day VAS score [median (interquartile
range, or IQR)] during second-trimester MTOP was 7 (5–8).
However, the reported delayed maximal VAS score, queried
at the follow-up visit, was higher [8 (7–10, pb.001)].T
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on reported pain was analyzed. Maximal pain VAS scores
[median (IQR)] were higher among women under 25 years
old compared to older women [7 (5–8) vs. 6 (5–8), p=.047],
and in women without previous vaginal deliveries compared
to those having previous vaginal deliveries [7 (5–8) vs. 5 (3–8),
p=.002].Maximal painVAS scoreswere lower in the 1-day than
in the 2-day mifepristone–misoprostol interval group [6 (5–8)
vs. 7 (5–9), p=.038] and among women with the highest
socioeconomic status (white-collar workers) compared
to others [5 (3–7) vs. 7 (5–8), p=.006]. Also, women
undergoing MTOP for fetal indications had lower VAS
scores than women undergoing MTOP for social indication
[4 (2–6) vs. 7 (5–8), p=.005].
None of the patients declined analgesics; few (9.2%)
managed without additional opiates. The number of additional
opioid doses [median (IQR)] was 2 (1–2). Most women
(97.4%) found NSAID medication at home adequate and
did not request opioids. Most women were satisfied with
the treatment of pain on the ward, and the satisfaction rate
[median (IQR)] was 8 (7–9).5. Discussion
Women reported moderate to severe pain (median VAS
over 6) associatedwith fetal expulsion during second-trimester
MTOP. Based on questioning 2-4 weeks after the MTOP
procedure, this pain is readily and intensely remembered.
This study provides new information on timing and risk
factors for experiencing pain and the recollection of pain in
second-trimester MTOP. However, in this secondary analysis,
the analgesics and their dosing varied. The duration of pain
could not be analyzed, and there is a small risk that the mostintense pain scores are lacking. The study sample is too small
to evaluate the impact of all demographic characteristics.
However, our results indicate that intense pain marks the
point of fetal expulsion, and analgesics should be given
frequently at that time. The finding of intense recollection of
severe pain is worrying. How does this experience affect
future plans for pregnancy and childbirth?
In conclusion, most women report moderate to severe
pain during second-trimester MTOP. Thus, more intense and
liberal use of analgesics during intense or increasing pain is
needed. The more severe the pain becomes, the more
difficult it may be to get it under control. Further studies are
needed to optimize the prevention and treatment of pain.
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